Jump to navigation

The University of Arizona Wordmark Line Logo White
UA Profiles | Home
  • Phonebook
  • Edit My Profile
  • Feedback

Profiles search form

Matthew Erisman

  • Assistant Clinical Professor, Psychiatry - (Clinical Series Track)
Contact
  • (520) 626-6336
  • AHSC, Rm. 7429
  • TUCSON, AZ 85724-5002
  • merisman@arizona.edu
  • Bio
  • Interests
  • Courses
  • Scholarly Contributions

Degrees

  • M.D. Medicine
    • Ross University, Portsmouth, Dominica
  • B.S.
    • Bishop's University, Sherbrooke, Quebec, Canada

Work Experience

  • Banner University Medical Center South (2020 - Ongoing)

Awards

  • Geriatric Psychiatry Fellowship
    • University of Arizona Geriatric Psychiatry Fellowship, Summer 2019
  • Psychiatry Residency
    • University of Arizona Psychiatry Residency, Summer 2015

Licensure & Certification

  • ABPN Certified Geriatric Psychiatrist, ABPN (2020)
  • ABPN Certified Psychiatrist (2019)
  • Arizona Medical Licensure. (2018)

Related Links

Share Profile

Interests

No activities entered.

Courses

2024-25 Courses

  • Geriatric Psychiatry
    PSYI 850H (Spring 2025)
  • Geriatric Psychiatry
    PSYI 850H (Fall 2024)

2023-24 Courses

  • Geriatric Psychiatry
    PSYI 850H (Spring 2024)

2020-21 Courses

  • Psychiatry Clerkship
    PSYI 813C (Spring 2021)
  • Psychiatry Clerkship Clinical
    PSYI 813C2 (Spring 2021)

Related Links

UA Course Catalog

Scholarly Contributions

Chapters

  • Duerden, M., Klugheit, M., & Erisman, M. (2024). Stimulant Use Disorder. In Treatment of Psychiatric Disorders Among Older Adults(pp 249-256). doi:10.1007/978-3-031-55711-8_18
    More info
    Treatment of stimulant use disorders is a growing public health concern in all age-groups, with older adults facing unique challenges and circumstances. Stimulant use disorder in older patient populations has not been well studied in the medical literature. But there is a consensus that successful screening, diagnosis, and treatment are necessary to help older patients manage the sequela of physical and psychiatric health concerns associated with stimulant use disorder. Evidence for treatment is in general support of primarily psychotherapeutic and psychosocial approaches, such as individual and group therapeutic interventions through such modalities as cognitive-behavioral therapy (CBT), contingency management (CM), 12-step programs, etc. There is no FDA approved medication for the treatment of stimulant use disorder. Data from a multitude of pharmacological treatment trials have yet to produce any sound evidence for specific interventions, but additional information and targeted studies still need to be considered in the future.

Journals/Publications

  • Karp, J., Erisman, M., & Singh, J. (2024). Balancing risks and benefits: Nuisance medication and cognitive decline in late-life. International Psychogeriatrics, 36(2). doi:10.1017/S1041610223000534
  • Karp, J. F., Erisman, M., & Singh, J. (2023). Balancing Risks and Benefits: Nuisance Medication and Cognitive Decline in Late-Life. International Psychogeriatrics, 1--6.
  • Vadiei, N., Garcia-Pittman, E. C., Dozier, C., Stephens, J., & Erisman, M. (2020). LESS IS MORE: APPROACHES TO DEPRESCRIBING IN A VARIETY OF PRACTICE SETTINGS. The American Journal of Geriatric Psychiatry. doi:10.1016/j.jagp.2020.01.038
  • Erisman, M., Parbtani, R., & Jaffer, F. (2016). Medical image of the week: arachnoid cyst. Southwest Journal of Pulmonary Critical Care & Sleep. doi:10.13175/swjpcc074-16
  • Puri, M., Hall, E., Erisman, M., & Vwich, Y. (2014). Acting strange after trying to 'get numb'. Current Psychiatry, 13(11).

Profiles With Related Publications

  • Jordan Karp
  • Michael Duerden

 Edit my profile

UA Profiles | Home

University Information Security and Privacy

© 2025 The Arizona Board of Regents on behalf of The University of Arizona.